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Abstract: We present the case of a kidney transplant patient (Cockroft-Gault estimated creatinine clear-
ance 14 ml/min) who was inadvertently eight-fold overdosed with a single dose of 500 mg intravenous
ganciclovir. To prevent the immunosuppressed patient from being exposed to severe risks of prolonged
ganciclovir overdosing, including potentially fatal bone marrow suppression and severe neurotoxicity, the
patient was treated with hemodiafiltration (HDF) to enhance drug elimination. Since the product label
reports a 50% decrease of ganciclovir plasma concentrations after intermittent hemodialysis (HD), two
HDF sessions were considered necessary to achieve a ฀75% elimination of the drug by precaution, despite
targeted intense HDF prescription. Ganciclovir plasma concentration data were obtained during both
HDF sessions and were analyzed retrospectively. Pharmacokinetic analysis revealed that prescribed HDF
successfully decreased drug plasma concentrations by ฀90%. This ganciclovir reduction ratio matched the
urea reduction ratio achieved (฀92%). Model-based assessment of ganciclovir dialysis clearance (estimated
to be 445 ml/min), accounting for its two-compartmental kinetics, was higher than urea dialysis clear-
ance (estimated to be 310 ml/min). This suggests potential relevant accumulation of ganciclovir into
blood cells, at least in this patient after overdosing. The amount (fraction) of drug removed by 1st HDF
was estimated to 269 mg (93% of total amount of 288 mg eliminated during the 1st HDF session; esti-
mated amount in the body prior to 1st HDF: 380 mg). A literature review was performed to summarize
and systematically compare available information on ganciclovir elimination during intermittent renal
replacement therapy. In conclusion, the high ganciclovir HDF clearance measured in our patient largely
exceeded previously reported elimination during HD, meaning that HDF prescription was highly efficient
in the present case, and that a second HDF session might not have been necessary. This finding may be
considered to guide renal replacement therapy in the scope of drug overdosing. It may also be evaluated
for ganciclovir dose adjustment in patients on chronic HD or HDF with high small solute clearance, since
a strong correlation between ganciclovir and urea elimination efficiency was observed.
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We present the case of a kidney transplant patient (Cockroft-Gault estimated creatinine
clearance 14 ml/min) who was inadvertently eight-fold overdosed with a single dose of
500 mg intravenous ganciclovir. To prevent the immunosuppressed patient from being
exposed to severe risks of prolonged ganciclovir overdosing, including potentially fatal
bone marrow suppression and severe neurotoxicity, the patient was treated with
hemodiafiltration (HDF) to enhance drug elimination. Since the product label reports a
50% decrease of ganciclovir plasma concentrations after intermittent hemodialysis (HD),
two HDF sessions were considered necessary to achieve a ≥75% elimination of the drug
by precaution, despite targeted intense HDF prescription. Ganciclovir plasma
concentration data were obtained during both HDF sessions and were analyzed
retrospectively. Pharmacokinetic analysis revealed that prescribed HDF successfully
decreased drug plasma concentrations by ≥90%. This ganciclovir reduction ratio
matched the urea reduction ratio achieved (≥92%). Model-based assessment of
ganciclovir dialysis clearance (estimated to be 445 ml/min), accounting for its two-
compartmental kinetics, was higher than urea dialysis clearance (estimated to be 310
ml/min). This suggests potential relevant accumulation of ganciclovir into blood cells, at
least in this patient after overdosing. The amount (fraction) of drug removed by 1st HDF
was estimated to 269 mg (93% of total amount of 288 mg eliminated during the 1st HDF
session; estimated amount in the body prior to 1st HDF: 380 mg). A literature review was
performed to summarize and systematically compare available information on ganciclovir
elimination during intermittent renal replacement therapy. In conclusion, the high
ganciclovir HDF clearance measured in our patient largely exceeded previously
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reported elimination during HD, meaning that HDF prescription was highly efficient in the
present case, and that a second HDF session might not have been necessary. This finding
may be considered to guide renal replacement therapy in the scope of drug overdosing. It
may also be evaluated for ganciclovir dose adjustment in patients on chronic HD or HDF
with high small solute clearance, since a strong correlation between ganciclovir and urea
elimination efficiency was observed.
Keywords: ganciclovir, valganciclovir, hemodialysis, hemodiafiltration, overdose, toxicity, blood-to-plasma
concentration ratio
BACKGROUND
Active cytomegalovirus (CMV) infection and disease is a major and
common complication in solid organ transplant recipients and is
associated with an increased risk of all types of infections, graft loss,
and with decreased survival. Intravenous ganciclovir is an antiviral
agent of choice for prevention and treatment of CMV infections in
this population (Kotton et al., 2018). It is a nucleoside analogue that
requires intracellular activation by phosphorylation via viral and
cellular kinases. The active triphosphate derivative acts as an
inhibitor of viral DNA polymerases and shows a long intra-
cellular half-life (~16.5h) compared to plasma half-life of the
unphosphorylated parent drug (2–4 h in patients with normal
renal function) (Scott et al., 2004).
Ganciclovir is a small molecule (molecular weight 255.2 Da)
with low protein binding (2%) and a small volume of distribution
(0.54–0.87 l/kg). It is mainly (>90%) cleared renally by
glomerular filtration and active tubular secretion (Cymevene
Swiss Product Information., ). Hence, dose adjustment in renal
impairment is necessary, with the elimination half-life of
ganciclovir being prolonged up to >10-fold in patients with
renal failure (30 h in patients with endstage renal disease)
(Lake et al., 1988). Pharmacological properties suggest efficient
elimination by hemodialysis (HD) (diffusive dialysis clearance)
and hemodiafiltration (HDF) (by both diffusive and convective
clearance) (Gotta et al., 2017; Gotta et al., 2020). The
manufacturer states that one HD session decreases ganciclovir
plasma concentrations by approximately 50% and suggests
considering HD to treat overdosing. Indeed, cases of fatal bone
marrow suppression have been reported in patients with renal
failure who were accidentally overdosed due to omission of dose
adjustment according to renal function (Ar et al., 2009). Under
therapeutic doses, neutropenia is a common side effect occurring
in approximately one third of patients, however in this setting, it
is mostly reversible. Further severe adverse reactions associated
with overdose may include neurotoxicity (confusion,
hallucinations, seizures, coma), acute renal failure, and
hepatitis (Cymevene Swiss Product Information., ).
We present a case of a kidney transplant patient with an
estimated creatinine clearance of 14 ml/min (Cockroft-Gault)
who accidentally received an eight-fold overdose with a single
dose of 500 mg ganciclovir and who was treated with HDF to
enhance drug elimination. According to available literature two
HDF sessions were performed to ensure an 75% elimination of
the drug. Ganciclovir plasma concentration data obtained during
HDF and analyzed retrospectively revealed that the first HDF
session successfully decreased drug plasma concentration by
92%, suggesting that a second HDF session might not have
been necessary.
We report our case according to the EQUATOR (Enhancing
the QUAlity and Transparency Of health Research) network
recommended guidelines for case studies on extracorporeal
treatments in poisonings (Lavergne et al., 2014).
CASE PRESENTATION
A 70-year old woman, who received a deceased donor renal
transplant in 2017, was treated with ganciclovir for CMV disease
with ulcerative esophagitis. In this patient weighing 44 kg with an
estimated creatinine clearance of 14 ml/min ganciclovir was started
at a reduced dose of 65 mg i.v. 22 months after transplantation. At
this time the patient was under immunosuppressive therapy with
tacrolimus and prednisolone, whereas mycophenolate mofetil was
paused due to intermitted neutropenia. Eleven days after start of
ganciclovir treatment, the patient received inadvertently an
overdose of ganciclovir with a single dose of 500 mg.
To prevent the immunosuppressed patient from being
exposed to severe risks of prolonged ganciclovir overdosing, a
first session of intermittent post-dilution HDF with standard
blood and dialysate flow (Table 1) and high ultrafiltration (34 L
per 4 h session) was started 5 h after recognizing the dosing error.
Using a dialysate containing 4 mmol/L potassium and additional
administration of potassium phosphate (30 mmol over 4 h)
successfully prevented hypokalemia and hypophosphatemia
despite highly intense HDF.
A complete summary of patient characteristics, concomitant
drug treatments, dialysis prescription, and efficiency in terms of
small molecule clearance (measured by urea clearance) is given
in Table 1.
Written informed consent was obtained from the patient for
publication of her case.
Pharmacokinetic Sampling and Calculated
Kinetic Parameters
Plasma samples for pharmacokinetic analysis were taken before,
during and after the two HDF sessions at in total eight time
points. Paired pre- and post-filter concentration samples (Cpre-
filter and Cpost-filter) were taken at three time points to calculate the
extraction ratio (ER) (Table 2A, Figure 1A):
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TABLE 2 | (A) Ganciclovir plasma concentrations measured during 2 dialysis sessions and calculated extraction ratio (ER) and reduction ratio (RR). (B) Predicted RR
from model simulations under different alternative scenarios.
(A) Ganciclovir measurements and calculated extraction ratio (ER) and reduction ratio (RR)
Session Time (h) Cpre-filter/Cpost-filter (mg/L) Calculated ER Calculated RR
1 Start = 0 11.59/4.38 (+2 min) 0.622
1 1 2.23/Not measured –
1 2 1.67/Not measured –
1 4 1.27/0.74 (+2 min) 0.417
1 Stop = 4.42 0.94/Not measured – 92%
2 Start = 11.25 1.01/0.18 (+5 min) 0.822
2 Stop = 16 <0.1/Not measured – >90%
Mean: 0.62
SD: ± 0.20
(B) Model simulations: predicted reduction ratio (RR)
Scenario (a) CLR,off [ml/min]
! predicted RR%






1 = present case 29 ! 93% 4.4 ! 93% 445 ! 93% 93%
2 15 ! 92% 4.0 ! 92% 315 (−30%) ! 89% 87%
3 0 ! 92% 3.5 ! 90% 100 (−80%) ! 64% 51%
The CLD value in scenario 2 corresponds to a ≈30% reduced clearance expectation in the absence of high ultrafiltration (according to urea kinetic modeling). The CLD value in scenario 3
corresponds approximately to the highest CLD value reported in the literature under chronic hemodialysis. Note that also different distribution parameters may change RR, those were
however assumed to be unchanged in model simulations.
ER, extraction ratio calculated as: (Cpre-filter – Cpost-filter)/Cpre-filter; RR, ganciclovir reduction ratio calculated as: (Cstart − Cstop)/Cstart × 100%; SD, standard deviation; Cpre-filter, ganciclovir
plasma concentration measured from sample drawn before the filter; Cpost-filter, ganciclovir plasma concentration measured from sample drawn after the filter.




Body weight 44 kg
Serum creatinine (pre-dialysis) 237 µmol/L
Estimated CLcrea (Cockroft-Gault) 14 ml/min
Hematocrit 27%
Serum albumin 24.1 g/L
Comedication tacrolimus, prednisolone, sulfamethoxazole/trimethoprim (prophylaxis), high-dose pantoprazole, chondroitin sulfate/hyaluronic
acid, unfractionated heparin (subcutaneous prophylaxis), low-dose acetylsalicylic acid, nebivolol, citalopram, low-dose quetiapine
Hemodiafiltration parameters1
Filter type FX CorDiax 100, Fresenius
(2.2 m2, KoAurea: 1545 ml/min (BC Renal Network, 2019))
Blood flow (QB) 350 ml/min (21 L/h)
Dialysate flow (QD) 525 ml/min (31 L/h)
Calculated ultrafiltration rate
(postdilution)
131 ml/min (7.9 L/h, or 34.8 L, 1st session) and
118 ml/min (7.1 L/h, or 40.1 L, 2nd session)
Session duration 265 min (4.42 h, 1st session) and
285 min (4.75 h, 2nd session)
Achieved urea (reference) clearance
Urea (pre- and post dialysis) 1st session: 21 and 1.6 mmol/L
2nd session: 2.2 and <0.5 mmol/L





according to Daugirdas JT 1993
(Daugirdas, 1993) (reported by
dialyzer)
1st session: 3.2 (reported: 2.41)
2nd session: >1.6 (reported: 2.74)
Predicted urea clearance from QB,
QD and filter KoAurea
230 ml/min (13.8 L/h)5
= 79% of in vitro clearance of 292 ml/min (Michaels, 1966) (17.6 L/h) (Michaels, 1966)
1The aggressive therapy was only possible with potassium at 4.1 mmol/l in dialysate and additional administration of 30 mmol potassium phosphate during first hemodiafiltration. During
the 2nd session dialysate with 5.1 mmol/l potassium was used. KoA urea, mass-transfer area coefficient of urea; URR, urea reduction ratio calculated as: (Cpre − Cpost)/Cpre × 100%.
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ER = Cpre filter − Cpost filter
 
=Cpre filter
The ganciclovir reduction ratio (RR) during HDF was
calculated in line with the calculated urea reduction ratio
(Table 1) from pre-HDF (Cstart, at start of HDF) and post-
HDF (Cend, after stopping HDF) ganciclovir pre-filter
concentrations:
RR = Cstart − Cendð Þ=Cstart  100%
Calculated ganciclovir HDF clearance (KHDF) was derived
from expected diffusive (Kd) and convective clearance (Kc),
accounting for the average ER measured:
Kd = QB  Rbp  ER = 350ml=min1 0:62 = 217ml=min
Where QB = prescribed blood flow, Rbp = blood-to-plasma
concentration ratio (assumed to equal 1 as average from in silico
(Lukacova et al., 2016) and in vitro (Perrottet et al., 2007)
estimates), and ER = average extraction ratio of 0.62.
Kc = UF SR  f = 118 131ml=min1 0:38 
=  45 − 50ml=min
With UF = ultrafiltration used (131 ml/min for 1st session and
118 ml/min for 2nd session, respectively), SR = solute ratio (or
sieving coefficient), assumed to equal 1 for a small molecule like
ganciclovir, and f = factor by which Kc is expected to be reduced
in the presence of diffusive clearance (=(1-Kd/Qb) in this
calculation (Depner, 2012))
Total calculated KHDF hence calculates to:
KHDF =  Kd + Kc = 262 267ml=min
Note that uncertainties exist concerning Rbp – in literature on
ganciclovir dialysis clearance (see below) no distribution into
blood cells has partly been assumed (i.e. Rbp = 1-hematocrit,
which would result in a lower Kd estimate for our patient of 217
ml/min × (1–0.27) = 158 ml/min, and KHDF of 203–208 ml/min),
while pharmacologically distribution into blood cells is necessary
for its mechanism of action.
Concentrations were measured by liquid chromatography
coupled to tandem mass spectrometry (LC-MS/MS) using an
accredited and validated method. Imprecision of the method
expressed as coefficient of variation was <7.3%, cumulative
trueness from the last four rounds of external quality
assessment (EQA) was −5.2%. EQA samples were obtained
from KKGT (Den Haag, The Netherlands).
Model-Based Estimation of Ganciclovir
HDF Clearance and Fraction of Drug
Removed by HDF
Due to uncertainties in KHDF calculation mentioned above, and
uncertainties in the volume of distribution to be used for
calculating the amount and fraction of drug removed by HDF
(Aremoved,HDF and fremoved,HDF, respectively), especially for this
drug which is known to have two-comparmental distribution
kinetics in plasma, a model-based pharmacokinetic analysis was
performed using NONMEM (version 7.4.1, Icon Development
Solutions, Ellicott City, MD) to estimate individual ganciclovir
renal and HDF clearances (CLR and CLHDF), and to derive
Aremoved,HDF and fremoved,HDF. Typical pharmacokinetic
parameters of a two-compartmental model were used
according to the population pharmacokinetic model published
by Caldes et al. developed from a population of solid organ
transplant patients with mean body weight of 66 kg (Caldés et al.,
2009) (mixed residual error: proportional error: 14.3%, additive
error: ± 0.465 mg/L). The last concentration measured below the
limit of quantification (LOQ) of 0.1 mg/L was set to LOQ/2.
In the used model the prior expectation (typical value) of
renal clearance (CLR) is a function of estimated creatinine
clearance (CLcrea − Cockroft-Gault estimate) (Caldés et al.,
2009):
prior CLR L=hð Þ = 7:49L=h CLcrea ml=minð Þ=57ml=minð Þ
= 7:49 14=57ð ÞL=h = 1:83L=h
Peripheral distribution parameters (peripheral volume of
distribution, V2, and inter-compartmental distribution
clearance Q) were additionally allometrically scaled by body
weight, since physiologically those kinetic parameters are
expected to be lower in a 44 kg patient as compared to a 66 kg
patient for a molecule that mainly distributes within total body
water:
V2 Lð Þ = 32:0 weight=66 = 21:3L
Q L=hð Þ = 10:2 weight=66ð Þ0:75= 7:52L=h
Total clearance (CL) was set equal to the sum of CLR and
CLHDF during hemodialysis and to CLR off-dialysis:
CL = CLR + CLHDF = CLtot,on    during analysis
CL = CLR = CLR,off     off-dialysis
Based on those parameters, expected inter-patient variability
(33% in prior CLR, 48% in central volume of distribution, V1, with
prior [typical] value of V1 = 31.9 L (Caldés et al., 2009)), and the
measured pre-filter ganciclovir concentration samples, individual
parameters of CLR, V1, and CLHDF were estimated using Bayesian
feedback to the following maximum a posteriori estimates: CLR =
1.8 (95% CI: 1.29–2.60) L/h [= 30 ml/min], V1 = 14.1 (95% CI: 7.4–
26.8) L, and CLHDF = 26.7 L/h (relative standard error <1%) [445
ml/min]. Inter-session variability in CLHDF was evaluated and was
—with an estimate of <1%—considered negligible. Based on
individual distribution and clearance parameters, the amount of
ganciclovir in the body prior to the first HDF session was predicted
to be 380 mg, which was reduced by 288 mg (76%) during the first
HDF session. 269 mg (93%) were predicted to be eliminated by
HDF (=Aremoved,HDF and fremoved,HDF) and 19 mg (7%) by patient’s
residual clearance (Figure 1C).
In a sensitivity analysis, CLHDF was fixed to calculatory KHDF,
which yielded individual estimates of CLR= 2.4 L/h [40 ml/min]
and V1 = 9.9 L, and a slightly worse model fit (P = 0.02, likelihood
ratio test). The amount of ganciclovir in the body prior to the
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first HDF session was predicted to 320 mg, which was reduced by
220 mg (69%) during the first HDF session. 191 mg (89%) were
predicted to be eliminated by HDF (=Aremoved,HDF and fremoved,
HDF) and 29 mg (13%) by patient’s residual clearance.
Modeling of Post-Filter Ganciclovir
Concentrations
Post-filter concentrations (Cpost-filter) were modeled assuming a
constant ER, to estimate the effective kinetic plasma flow through
the filter (QEFF) (Atkinson and Umans, 2009):
Cpost filter = Cpre filter  1ERð Þ = Cpre filter  1CLHDF=QEFFð Þ
Assuming diffusive clearance to represent the major
mechanism of elimination for a small molecule during HDF
(Tattersall and Blankestijn, 2019), QEFF would be limited by the
blood flow (QB) through the filter, but can exceed QB for
molecules that accumulate in blood cells, i.e. for drugs with a
blood-to-plasma concentration ratio (Rbp) >1, since QEFF = QB ×
Rbp (Atkinson and Umans, 2009). For molecules that do not
distribute into blood cells QEFF would in turn equal the plasma
water flow, i.e. QEFF = QB × (1 − hematocrit). In HDF, QEFF can
further increase by high ultrafiltration.
Allowing for inter-session variability in the ER (suggested in
Table 2), QEFF was estimated to be 47.4 L/h (relative standard
error <1%) [788 ml/min], corresponding to a mean ER of 0.56,
with considerable inter-session variability of 49%. The
proportional residual error in predicted Cpost-filter concentrations
was estimated to be 25%, an additive error was not quantifiable.
Modelling Cpost-fi l ter did not affect the ganciclovir
CLHDF estimate.
Ganciclovir Model Simulations
Model simulations using different hypothetical CLR, dialysis
duration, and dialysis clearance were performed using Berkeley
Madonna (version 8.3.18) to evaluate the impact of those
parameters on the reduction ratio (Table 2B), and to better
compare our results to literature (see below).
Comparative Kinetic Analysis of Urea as
Reference Solute
Urea—just like ganciclovir—follows two-compartmental
distribution kinetics (Clark et al., 1999). Urea dialysis clearance
(CLHDF,urea) was also estimated kinetically using a model-based
analysis. Urea distribution parameters (V1, V2, Q) and residual
error were fixed to values predicted from a urea kinetic model
accounting for weight-based changes in inter-compartmental
clearance (Gotta et al., 2020). Renal urea clearance (CLR,urea) was
assumed to be related to creatinine clearance (CLR,crea as follows:
CLR,urea = CLR,crea  0:85=1:15 = 10:3ml=min
considering their correlation with glomerular filtration rate
(GRF), which is approximately 15% overpredicted by CLR,crea
(undergoing tubular secretion) and 15% underpredicted by
CLR,urea (Almond et al., 2008).
The urea generation rate was initially fixed to 0.104 mmol/
min (Clark et al., 1999). In a second step an individual value was
estimated using prior values estimated from a small population
of patients on chronic HD (prior mean: 0.17 mmol/min, inter-
individual variability: 38%) (Pfister et al., 2004). The last
concentration measured below the LOQ of 0.5 mmol/L was set
to LOQ/2.
Total urea clearance (CLurea) was set equal to the sum of CLR,
urea and CLHDF,urea during hemodialysis and to CLR,urea off-
dialysis:
CLurea = CLR,urea + CLHDF,urea = CLtot,urea,on  during dialysis
CLurea = CLR,urea = CLR,urea,off   off  dialysis
This approach yielded an estimate of total CLHDF,urea of 310
ml/min, i.e. larger than the diffusive clearance mechanistically
predicted from filter characteristics, blood flow, and dialysate
flow (predicted urea clearance: 230 ml/min, Table 1) (Gotta
et al., 2020). The individual urea generation rate was estimated to
0.056 mmol/min.
The complete NONMEM model codes for ganciclovir and
urea can be found in the supplemental data. All model
predictions are shown in Figure 1.
Review of the Literature
Publications relating to intermittent renal replacement therapy for
comparison of our data were searched on MEDLINE during
October 2019 using “renal dialysis” (MeSH) AND (“ganciclovir”
OR “valganciclovir”). This search resulted in 32 references, whose
abstracts were screened for pharmacokinetic data, which were then
extracted from the full publication. In total seven publications
reporting pharmacokinetic data in patients on intermittent
hemodialysis were identified. Reported and calculated
pharmacokinetic parameters of interest are summarized in Table 3.
DISCUSSION
We present a case of an inadvertent eight-fold ganciclovir overdose
in a 70-year-old kidney transplant patient, successfully treated with
two sessions of intermittent HDF. Retrospective analysis of
ganciclovir pharmacokinetic data revealed that HDF was much
more efficient at removing ganciclovir from the patient’s plasma
(reduction ratio: ≥90%) than previously reported for endstage-renal
disease patients on chronic HD (50–67%, Table 3).
While it must be noted that residual renal ganciclovir clearance
in our patient (estimated to be 30 ml/min by Bayesian feedback, i.e.
twice her creatinine clearance) may have contributed to the high
reduction ratio during a HDF session of 4.4 h, model-based
analysis showed that it contributed to only 7% of total clearance
during HDF (estimated to be 475 ml/min). A model-based analysis
was considered necessary to calculate CLHDF due to the delayed
two-compartmental distribution kinetics of the drug (Czock et al.,
2002; Caldés et al., 2009) and since assessment of dialysis clearance
by the ER only is complicated by limited knowledge about the
distribution into blood cells that would be required to make correct
assumptions about the effective pharmacokinetic plasma flow
through the filter (Atkinson and Umans, 2009). The ganciclovir
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CLHDF estimate of 445 ml/min was very close to the sum of
prescribed blood flow and ultrafiltration rate (350 + 131 ml/min =
481 ml/min) and was higher than urea dialysis clearance estimated
(310 ml/min). This suggests an accumulation of ganciclovir in the
blood cells in this patient (Rbp > 1). To our knowledge, Rbp has not
been measured in vivo for ganciclovir. Based on its pharmacologic
action, requiring intracellular phosphorylation leading to a long
intra-cellular half-life (discussed in the introduction) and
accumulation in peripheral blood mononuclear cells (Billat et al.,
2016), it may be hypothesized that an Rbp > 1 would
pharmacologically be expected. An erythrocyte/plasma value of
1.11 has indeed been measured in vitro by Perrottet et al. (2007).
We acknowledge that an in silico estimate of 0.89 has been
proposed (Lukacova et al., 2016)). in contrast to our expectation,
which is however usually based on physiochemical properties only
(e.g. polarity and lipophilicity) (Peters, 2012) and which may
ignore active transmembrane transport mechanisms known for
ganciclovir (Lukacova et al., 2016). If ganciclovir would distribute
like the small molecule urea (molecular weight: 60 Da)
homogenously and passively between plasma and red blood cells
(Rbp = 1), CLHDF of ganciclovir could physiologically not exceed
the estimated CLHDF,urea value of 310 ml/min. Collection of
dialysate and ultrafiltrate to measure the recovered ganciclovir
amount and CLHDF directly would have been additionally useful as
gold-standard method, but was not practical. Serial measurements
of intra-cellular ganciclovir and application of a multi-
compartment distribution model (Billat et al., 2016) could have
further enhanced our mechanistic understanding of the high
CLHDF calculated. Importantly, highly efficient elimination of
ganciclovir by HDF as reported here may not be sufficient to
prevent hematologic and neurologic toxicity completely as
intracellular accumulation still may occur. Our patient did not
show any signs of neurotoxicity and she recovered from
intermittent leukopenia, which was apparent before overdosing
and may have other reasons as cytotoxicity due to CMV infection.
Interestingly however, there was a very strong correlation
between the ganciclovir and urea reduction ratio calculated (both
ratios calculated to 92% during the first session), which may be
an approximation for the amount of drug removed during HDF.
This may suggest—independent of red blood cell distribution—
that efficiency of urea removal can be used as a surrogate marker
for ganciclovir removal. The estimated CLHDF,urea of 310 ml/min
exceeded the mechanistically predicted diffusive in vivo urea
clearance of 230 ml/min by 35%, suggesting significant
contribution of convective clearance by the high ultrafiltration
used in this HDF setting. The high blood flow compared to cases
TABLE 3 | Review of existing literature (chronologically ordered) on ganciclovir elimination during different types of intermittent renal replacement therapy (RRT) and








Lake et al., 1988
(n = 1)
HD (4 h) Cordis Dow 4000 Low
UF
QB = 250 ml/
min
QD: -
CLD = 68.5 per
1.76 m2






Sommadossi et al., 2019
(n = 2)
HD (4 h) – QB = 300 ml/
min
QD = 800 ml/
min
– ER: -
RR = 53 ± 11%
(up to 70%)
Swan et al., 1991
(n = 1)
HD (4 h) Lundia IC 3L Gambro,
0.8 m2








Combarnous et al., 1994
(n = 1)
HD (5 h) high permeability dialyzer,
1.1 m2
QB = 200 ml/
min






Pescovitz et al., 1998
(n = 6)
HD (4 h) – – – ER: -
RR = 53%
Czock et al., 2002
Czock and Rasche, 2004
(n = 6)





(visually) (Czock et al., 2002)/≈49–58% (Czock and
Rasche, 2004),*2








(2.2 m2, KoAurea: 1545
ml/min)
QB = 350 ml/
min









RR, reduction ratio, calculated as 1-Cend/Cstart = (Cstart− Cend)/Cstart × 100%; ER, extraction ratio, calculated as (Cpre-filter – Cpost-filter)/Cpre-filter; QB, blood flow (ml/min); QD, dialysate flow
(ml/min); UF, ultrafiltration volume; CLD, ganciclovir dialysis clearance reported or calculated; CLR,off, residual renal ganciclovir clearance off-dialysis; CLtot,on, total ganciclovir clearance
during dialysis (=CLD + CLR,off). *
1Note that distribution exclusively to plasma was assumed in the calculation. *2Assuming this value to approximate the fraction of dose removed from the
body, the lower estimate accounts for rebound.
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reported in the literature probably also contributed to a high
diffusive clearance. The difference of 80 ml/min, relating to
convective urea clearance, corresponds to 0.61–0.67 of the
ultrafiltration rate used. This fraction may be interpreted as net
sieving coefficient, which is expected to be reduced in the
presence of diffusion (Tattersall and Blankestijn, 2019)
compared to its expected value of 1.
In conclusion, this case illustrates highly efficient elimination of
ganciclovir by intermittent HDF in a patient treated for inadvertent
overdose potentially associated with intermittent leukopenia.
Ganciclovir elimination by targeted intense HDF largely exceeded
elimination reported by previous publications for patients on
intermittent HD. The high elimination in the present case may
be explained by several factors. First, a relevant contribution of
convection to CLHDF at the high ultrafiltration rate used could be
quantified for the reference molecule urea. Second, the blood flow
of 350 ml/min was higher and the HDF session duration of 4.4–4.7
h was longer than in previous references reporting on ganciclovir
elimination during HD. Third, while it is difficult to conclude on the
importance offilter characteristics, since details were frequently not
provided in the literature, the filter used in this case may have been
characterized by a larger surface area and higher dialytic efficiency
than filters used in the past. In fact, some drug dose
recommendations for patients on RRT issued before the year
2000 are likely outdated due to advanced technology (Mueller
and Smoyer, 2009). The reduction ratio of reference molecules
like urea, which is routinely assessed during HD and HDF, could be
evaluated as an indicator of ganciclovir removal in future studies.
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FIGURE 1 | (A) Ganciclovir plasma concentration measured (black dots: pre-
filter, gray dots: post-filter) and model-predicted individual concentration-time
profile since last normal (for renal function adjusted) ganciclovir dose (black
line: pre-filter and intra-dialytic plasma concentration, dashed line: post-filter
concentration assuming a constant extraction ratio within each
hemodiafiltration session). ^: time and dose of i.v. ganciclovir administered.
Gray bars indicate time on hemodiafiltration. (B) Urea concentration
measured (dots) and model-predicted urea concentration-time profile. Open
circles: (pre-filter) concentrations below limit of quantification (LOQ) (0.1 for
ganciclovir, 0.5 mmol/L for urea), plotted at LOQ/2. (C) model-predicted
amount of ganciclovir in the body (black solid line), and predicted total
amount eliminated since start of first HDF session (dashed line), which is the
sum of elimination by residual ganciclovir clearance of the patient (yellow
shaded area, limited by dotted line) and HDF (red shaded area).
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